Health News Archive - May 19, 2010
Drugs should be developed to target gene fusions in prostate cancer, research shows.
WARRENDALE, Pa., May 19 /PRNewswire/ -- Today, MEDRAD, Inc. and Pinestar Technology, Inc. announced plans to enable data communication between MEDRAD's Intego(TM) PET Infusion System and Pinestar's Nuclear Medicine Information System (NMIS).
MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that Thomas J. Schall, Ph.D., the Company's President and Chief Executive Officer is a finalist for the Ernst & Young Entrepreneur Of The YearÂ® 2010 Award in Northern California.
Cystic Fibrosis Foundation Drug Development Model Spawns More Than 30 Promising Therapies BETHESDA, Md., May 19 /PRNewswire-USNewswire/ -- National Institutes of Health (NIH) Director Francis S.
The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.
Children who undergo brief periods of intense exercise may exhibit lung dysfunction or other symptoms similar to those experienced by asthma patients, even when no history of asthma exists.
Early tracheotomy in ICU patients on mechanical ventilation (MV) did not reduce mortality when compared to later tracheotomy in a study of cardiac surgery patients requiring prolonged ventilation in a Paris study.
Army scientists have discovered a way to "trick" the bacterium that causes anthrax into shedding its protective covering, making it easier for the body's immune system to mount a defense.
KALAMAZOO, Mich., May 19 /PRNewswire-FirstCall/ -- Stryker Corporation (NYSE: SYK) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the actions undertaken to address issues raised in two Warning Letters received in 2007 and 2009 are sufficient.
NEW YORK, May 19 /PRNewswire/ -- After delivering a unanimous verdict against Novartis on all counts and awarding 12 former Novartis sales reps $3.36 million in compensatory damages yesterday, a New York jury today delivered a stronger dose of the same medicine.